[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100631620":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":30,"locations":40,"responsibleParty":54,"collaborators":58,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":65,"sex":71,"minAge":72,"maxAge":25,"enrollmentInfo":73,"targetDuration":25,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":86,"whyStopped":25,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"Charite University, Berlin, Germany","OTHER",[8,13],{"label":9,"type":6,"description":10,"interventionNames":11},"Control (ChatGPT Control Condition)","Participants in this arm engage in a three-turn conversation with ChatGPT. The AI's role is to:\n\n* Discuss the participant's perception of how dangerous ovarian cancer is.\n* Provide factual information on prevalence, lifetime risk, mortality rates, and general epidemiology.\n* Avoid any mention of screening tests, guideline recommendations, or screening benefits\u002Fharms.\n* Keep responses concise (5-8 sentences per turn).\n* Begin by reacting to the participant's opening question: \"In your mind, how dangerous is ovarian cancer?\"",[12],"Behavioral: ChatGPT - Control",{"label":14,"type":15,"description":16,"interventionNames":17},"Experimental (ChatGPT Evidence-Based Screening Discussion)","EXPERIMENTAL","Participants in this arm engage in a three-turn conversation with ChatGPT. The AI's role is to:\n\n* Ask participants to elaborate on their reasons for recommending ovarian cancer screening.\n* Provide clear, evidence-based information about benefits and harms of ovarian cancer screening in average-risk women.\n* Refer to key findings from large trials (e.g., PLCO, UKCTOCS) with absolute numbers (false-positive rates, unnecessary surgeries, complication rates, lack of mortality benefit).\n* Summarize positions of major U.S. guidelines (e.g., USPSTF, ACOG), including recommendation against routine screening in asymptomatic, average-risk women.\n* Evaluate the evidence and state whether routine screening is supported based on current data.\n* Maintain a respectful, non-judgmental tone; critique evidence, not the participant.\n* Keep responses concise (5-8 sentences per turn).\n* Begin by responding to the participant's opening question: \"Why do you recommend ovarian cancer screening?\"",[18],"Behavioral: ChatGPT - Evidence-Based Screening Discussion",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"BEHAVIORAL","ChatGPT - Control","Three-turn conversation; discusses ovarian cancer risk and epidemiology; avoids screening topics; concise responses (5-8 sentences).\n\nMode of Delivery: Online chat interface; participant interacts directly with ChatGPT.",[9],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"ChatGPT - Evidence-Based Screening Discussion","Three-turn conversation; asks participants about screening rationale; provides evidence-based info on benefits\u002Fharms, trial data, guideline positions; concise responses (5-8 sentences).\n\nMode of Delivery: Online chat interface; participant interacts directly with ChatGPT.",[14],[31,36],{"name":32,"role":33,"phone":34,"phoneExt":25,"email":35},"Odette Wegwarth, Prof. Dr.","CONTACT","+49 30 450 531 074","odette.wegwarth@charite.de",{"name":37,"role":33,"phone":38,"phoneExt":25,"email":39},"Miriam K Rumpel, M.Sc.","+49 30 450 531 058","miriam.rumpel@charite.de",[41],{"facility":42,"status":25,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":25},"Charité - Universitätsmedizin Berlin","Mitte","State of Berlin","10117","Germany","DE",{"type":49,"coordinates":50},"Point",[51,52],13.40489,52.52003,{"lat":52,"lon":51},{"type":55,"investigatorFullName":56,"investigatorTitle":57,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"PRINCIPAL_INVESTIGATOR","Odette Wegwarth","Prof. Dr.",[59,61],{"name":60,"class":6},"Max Planck Institute for Human Development",{"name":62,"class":6},"German Research Foundation","100631620","ovarian-cancer-screening-and-ai-100631620",false,"NCT07503054","Ovarian Cancer Screening and AI","AI on Ovarian Cancer Screening Attitudes in Gynecologists","AI-OCS-Gyn","Inclusion Criteria:\n\n* gynecologists in outpatient care who provide ovarian cancer screening to asymptomatic, average-risk women (not guideline consistent)\n\nExclusion Criteria:\n\n* gynecologists in inpatient care\n* gynecologist in outpatient care who do NOT provide ovarian cancer screening to asymptomatic, average-risk women (guideline consistent)","ALL","24 Years",{"count":74,"type":75},350,"ESTIMATED","INTERVENTIONAL",[78],"NA","Gynecologists frequently overestimate the benefits and safety of ovarian cancer screening. AI-supported discussions may help correct these misperceptions. This study tests whether an AI-guided conversation about the evidence on ovarian cancer screening can improve gynecologists' knowledge and reduce non-evidence-based screening recommendations, compared with a control AI discussion on ovarian cancer prevalence.",[81],"Ovarian Cancer Screening Recommendations by Gynecologists",[83,84,85],"ovarian cancer screening recommendations","AI-based conversational intervention","gynecologists' knowledge on ovarian cancer screening","NOT_YET_RECRUITING","2026-03-25",{"date":89,"type":90},"2026-03-31","ACTUAL",{"date":92,"type":75},"2026-03-27",{"date":94,"type":75},"2026-04-30",{"name":5,"class":6},1]